Looking to sell BillionToOne stock or options?Contact us
BillionToOne has developed a molecular counter platform designed to enhance the precision of cell-free DNA testing. Their pan-cancer oncology test, which is tumor-naive, accurately measures tumor load from a blood sample, aiding in monitoring responses to therapy. Additionally, BillionToOne's prenatal testing procedure utilizes quantitative biology and statistical learning approaches to maximize the signal-to-noise ratio and detect single-gene disorders. This enables expectant mothers to identify disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a straightforward blood test.
Shahram Seyedin-Noor, Keyan Li, Adams Street Partners, Pacific 8 Ventures, Metaplanet Holdings, Endpoint Ventures, Lombardstreet Ventures, NewDo Venture, 500 Emerging Europe, Hummingbird Ventures, Baillie Gifford, Start Capital, U.S. Department of Health and Human Services, Enis Hulli, Norwest Venture Partners, Sandy Kory, 500 Global, Civilization Ventures, Wei Guo, MengKe Li, Rina Onur, Luigi Bajetti, Lawrence Diao, Fifty Years, Y Combinator.
We have an even better solution: The Collective Exchange Fund
Get in touch and see if we can help you